ArticleFrontiers in microbiology2025
Development of a yeast-based CRISPR genome editing system for feline coronavirus.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Feline infectious peritonitis (FIP), caused by feline coronavirus (FCoV), is a highly lethal disease characterized by systemic organ infection in cats. Current challenges of FIP include the absence of definitive diagnostic criteria, effective vaccines, and targeted therapies. Developing a robust genome editing toolkit is therefore critical to unraveling FCoV replication and pathogenesis mechanisms, elucidating viral protein functions, and identifying promising diagnostic and therapeutic targets. Methods: In this study, we developed a yeast-based CRISPR genome editing system compatible with a TAR-generated FCoV infectious clone, enabling gene deletion, gene insertion, and point mutation with high efficiencies and accuracies. Results and discussion: This system not only will contribute to a better understanding of the pathogenic mechanisms of FCoV but also serves as a valuable platform for vaccine development. Furthermore, it offers a possible strategy for genome editing and reverse genetics for other coronaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.